Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

705 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Busulfan-fludarabine- or treosulfan-fludarabine-based myeloablative conditioning for children with thalassemia major.
Lüftinger R, Zubarovskaya N, Galimard JE, Cseh A, Salzer E, Locatelli F, Algeri M, Yesilipek A, de la Fuente J, Isgrò A, Alseraihy A, Angelucci E, Smiers FJ, La La Nasa G, Zecca M, Fisgin T, Unal E, Kleinschmidt K, Peters C, Lankester A, Corbacioglu S; EBMT Pediatric Diseases, Inborn Errors Working Parties. Lüftinger R, et al. Among authors: unal e. Ann Hematol. 2022 Mar;101(3):655-665. doi: 10.1007/s00277-021-04732-4. Epub 2022 Jan 9. Ann Hematol. 2022. PMID: 34999929
Outcome of autologous hematopoietic stem cell transplantation in children and adolescents with relapsed or refractory Hodgkin's lymphoma.
Hazar V, Kesik V, Aksoylar S, Karakukcu M, Ozturk G, Kupesiz A, Atas E, Oniz H, Kansoy S, Unal E, Tanyeli A, Erbey F, Elli M, Tacyildiz N, Karasu GT, Kocak U, Anak S, Yilmaz Bengoa S, Sezgin G, Atay D, Unal E, Uygun V, Kurucu N, Kaya Z, Yesilipek A; Turkish Pediatric Bone Marrow Transplantation Study Group (TPBMT-SG). Hazar V, et al. Among authors: unal e. Pediatr Transplant. 2015 Nov;19(7):745-52. doi: 10.1111/petr.12573. Epub 2015 Sep 8. Pediatr Transplant. 2015. PMID: 26346042
Allogeneic hematopoietic stem cell transplantation in leukocyte adhesion deficiency type I and III.
Bakhtiar S, Salzmann-Manrique E, Blok HJ, Eikema DJ, Hazelaar S, Ayas M, Toren A, Goldstein G, Moshous D, Locatelli F, Merli P, Michel G, Öztürk G, Schulz A, Heilmann C, Ifversen M, Wynn RF, Aleinikova O, Bertrand Y, Tbakhi A, Veys P, Karakukcu M, Kupesiz A, Ghavamzadeh A, Handgretinger R, Unal E, Perez-Martinez A, Gokce M, Porta F, Aksu T, Karasu G, Badell I, Ljungman P, Skorobogatova E, Yesilipek A, Zuckerman T, Bredius RRG, Stepensky P, Shadur B, Slatter M, Gennery AR, Albert MH, Bader P, Lankester A. Bakhtiar S, et al. Among authors: unal e. Blood Adv. 2021 Jan 12;5(1):262-273. doi: 10.1182/bloodadvances.2020002185. Blood Adv. 2021. PMID: 33570653 Free PMC article.
The Efficiency and Toxicity of Mifamurtide in Childhood Osteosarcoma.
Tacyildiz N, Incesoy Ozdemir S, Unal E, Berber M, Dincaslan H, Yavuz G. Tacyildiz N, et al. Among authors: unal e. J Pediatr Hematol Oncol. 2018 Aug;40(6):e373-e376. doi: 10.1097/MPH.0000000000001236. J Pediatr Hematol Oncol. 2018. PMID: 29889801
A targeted salvage therapy with Brentuximab vedotin in heavily treated refractory or relapsed pediatric Hodgkin lymphoma patients before and after stem cell transplantation.
Taçyıldız N, Tanyıldız HG, Ünal E, Dinçaslan H, Asarcıklı F, Aksoy BA, Vatansever G, Yavuz G. Taçyıldız N, et al. Among authors: unal e. Turk J Pediatr. 2019;61(5):671-676. doi: 10.24953/turkjped.2019.05.005. Turk J Pediatr. 2019. PMID: 32104998 Free article.
Tacyildiz N, Tanyildiz HG, Unal E, Dincaslan H, Asarcikli F, Adakli Aksoy B, Vatansever G, Yavuz G. ...Brentuximab vedotin (BV) is an antibody-drug conjugate that targets the tumor necrosis receptor family protein member CD30 positive malignancies via an anti-CD30 m …
Tacyildiz N, Tanyildiz HG, Unal E, Dincaslan H, Asarcikli F, Adakli Aksoy B, Vatansever G, Yavuz G. ...Brentuximab vedotin (BV …
Serum levels and differential expression of intercellular adhesion molecule-1 in childhood leukemia and malignant lymphoma: prognostic importance and relationship with survival.
Tacyildiz N, Yavuz G, Gozdasoglu S, Unal E, Ertem U, Duru F, Ikinciogullari A, Babacan E, Ensari A, Okcuoglu-Cavdar A. Tacyildiz N, et al. Among authors: unal e. Pediatr Hematol Oncol. 1999 Mar-Apr;16(2):149-58. doi: 10.1080/088800199277470. Pediatr Hematol Oncol. 1999. PMID: 10100275 Clinical Trial.
705 results